As per a report, Novartis, a pharmaceutical company in India was being claimed to be planning to quit from stock exchange. The company opened on Monday with a rise of 12% and there was a further increase by 2% amounting to Rs 864.95 on BSE.

An all new vaccine has been put against meningitis B that apparently will be scheduled for the next year with Novartis claiming that the shot has been tested in case of human beings.

Novartis’ drug, Bexsero has been bestowed by health experts who state that the jab will aid in a sharp decline in the number of children death due to the disease.

Pharmaceutical firm Novartis India has declared its first quarter financial results for the fiscal year 2010-11. The company has informed that there has been a marginal decline in its net profit for the June quarter of this year against the similar period last year.

Novartis India has posted a net profit of Rs 31.53 crore for this quarter which was reported to be Rs 31.76 crore for the corresponding quarter last year.

However, there has been a hike in company's net sales during the April-June period of fiscal year 2010 against last year.

One of the leading pharmaceutical companies, Array BioPharma has signed a deal with the Novartis AG.

The deal is a licensing deal for the experimental cancer drug candidates of Array BioPharma. The Swiss drug maker Novartis AG is also ready for the license arrangement with the America Inc.

The financial aspects of the contract have been published. Array has to pay the Swiss company $45 million as upfront payments and $422 million in milestones.

However, the share prices of the American pharmaceutical company have gone up by 30% just after the announcement of the deal.

Agriflu, a seasonal flu vaccine manufactured by Novartis Vaccines and Diagnostics has been approved by the U.S. Food and Drug Administration (FDA), however, it offers no protection against the H1N1 virus, commonly known as swine flu.
 
As demonstrated by Novartis, the vaccine induces anti-body levels in the blood effective enough to prevent seasonal influenza, though further studies are still required for Agriflu, available in single dose, pre-filled syringes that do not contain preservatives, for 18-plus adults and administered as a single injection in the upper arm.

Novartis India Ltd. - OTC Business Unit, has announced the launch of Otrivin in a Nasal Spray format in Indian market.

It should be noted that Otrivin has been the market leader in the Nasal Decongestant category, and has been trusted by health care professionals for several decades. However, it is now available as an OTC nasal decongestant in spray form that acts directly by constricting the blood vessels in the nasal tissues leading to relief from nasal congestion.

Geneva - Novartis, the Swiss drug-maker, began its clinical trials for a vaccine for swine flu at the end of last month, a spokesman said Monday.

In an email, Eric Althoff, from the Basle-based pharmaceutical giant, said the company's researchers expect to recruit some 6,000 people in various countries for the testing.

The data would likely be submitted to health authorities in September, Althoff said, with the goal of starting deliveries of a vaccine during the final quarter of the year.

The U. S. Food and Drug Administration announced Thursday it is conducting a safety review of the asthma drug Xolair after receiving reports of increased risk of heart attack, abnormal heart rhythm, heart failure, and stroke among patients who use it.

The drug Xolair (omalizumab) made by Genentech and co-marketed by Novartis, given by injection, is approved for use by adults and adolescents (12 and older) with moderate to severe persistent asthma whose symptoms are not well controlled with inhaled corticosteroids.